Abstract：Objective: To study comparison of adverse reactions between changchun dixin (VDS) and vincristine (VCR) in the application of acute lymphocytic leukemia in children. Methods: 90 patients with acute lymphoblastic leukemia in our hospital were selected from February 2013 to February 2015, there were 45 cases in VDS group and 45 in the VCR group. VDS group was treated with VDS3mg/m2. VCR group was treated with vcr1.5mg /m2. The clinical efficacy and clinical characteristics of the two groups were compared with the average hospitalization expenses. The adverse reactions of the two groups were recorded. Results: After treatment, there was no statistically significant difference between CR rate, early death rate and remission time in both groups (P >0.05). After treatment, there was no significant difference in clinical features between the two groups (P>0.05); In the two groups of patients, the hospitalization expenses include drug charge, examination fee, treatment fee, nursing fee, blood transfusion fee, material fee and bed fee. The average hospitalization expense of the VDS group was 25,995 yuan/person, and the average hospitalization expense of the VCR group was 34245 yuan/person, and the difference between the two groups was statistically significant (P=0.001). The incidence of thrombocytopenia, anemia and neurotoxin in the VDS group was lower than that in the VCR group, and the difference was statistically significant (P<0.05). Conclusion: VDS and VCR early curative effect of treatment of children with acute lymphocytic leukemia has no obvious difference, but the use of VDS for children with acute lymphocytic leukemia incidence of adverse reactions and hospitalization costs are lower than using a VCR.
王兴,白明辉,季佳,刘秋红. 长春地辛与长春新碱在儿童急性淋巴细胞性白血病应用中不良反应的对比[J]. 河北医学, 2018, 24(10): 1751-1754.
WANG Xing, BAI Minghui, JI Jia, et al. Comparison of Adverse Reactions between Vindesine and Vincristine in Children with Acute Lymphoblastic Leukemia. HeBei Med, 2018, 24(10): 1751-1754.
[1] 王鸿武,林丽敏.儿童急性淋巴细胞性白血病化疗前后红细胞体积分布宽度的变化及临床意义[J].吉林医学,2016,37(12):2887~2888. [2] 卢榕,陈志奇.儿童急性淋巴细胞白血病免疫分型特点分析[J].山西职工医学院学报,2016,26(05):34~36. [3] Maude SL, Laetsch TW, Buechner J et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl Med,2018,378(5):439~448. [4] 陈丽.长春地辛和长春新碱治疗儿童急性淋巴细胞白血病疗效比较[J].中国处方药,2017,15(09):97~98. [5] 李妍,史利欢,郭明发,等.儿童急性淋巴细胞白血病免疫分型特征及其临床意义[J].疾病监测与控制,2017,11(11):929~930. [6] Tahir IM, Iqbal T, Jamil A et al. Association of BCL-2 with oxidative stress and total antioxidant status in pediatric acute lymphoblastic leukemia[J].Biol Regul Homeost Agents,2017,31(4):1023~1027. [7] 陈红.儿童急性淋巴细胞性白血病化疗期的护理分析[J].中国现代药物应用,2014,8(05):185~186. [8] 皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统--通用不良反应术语标准4.0版[J].肿瘤,2012,32(02):142~144. [9] 梁宇,王西阁,赵雪莲,等.儿童急性髓系白血病治疗分析[J].中国民康医学,2017(23):76~79. [10] 徐宏斌,盛小娟,孟玉娟,等.急性淋巴细胞性白血病患者血清及脑脊液胰岛素及白细胞介素相关指标的变化研究[J].中国现代医学杂志,2016,26(16):39~42. [11] 李英华,郭秀芬,王冬梅,等.类儿童化疗方案治疗初治青少年及年轻成人急性淋巴细胞性白血病的临床研究[J].重庆医学,2013,42(01):61~63. [12] Larfors G, Glimelius I, Eloranta S et al. Parental age and risk of lymphoid neoplasms[J]. Am Epidemiol,2017,186(10):1159~1167. [13] 林愈灯.2014年儿童血液肿瘤研究进展[J].循证医学,2015,15(01):22~24.
2018, Vol. 24 
冀公网安备13080202000677号